Truvada

Roundup Cases are
Settling

TRUVADA – WHAT THEY KNEW, WHEN THEY KNEW IT

When HIV/AIDS first hit, panic ensued as it was first considered a death sentence. The pharmaceutical industry was racing to find a treatment or a cure. TDF (later Viread, Truvada, and other names) entered the market and gave hopes of a potential miracle drug, rendering HIV a chronic disease. However, it caused kidney failure and bone deterioration. It seemed that patients were left with a choice – either death by AIDS or kidney failure and bone loss.  Little did they know that Gilead, the manufacturer of Truvada and other such drugs, had a safer, more effective alternative design in their back pocket – TAF. They sat on this alternative in silence for over a decade and moved forward with TDF drugs in order to maximize the profit from its first patent with TDF.

Gilead’s TDF drugs included – Viread, Truvada, Atripla, Complera, and Stribild, Truvada for PrEP

EARLY INDICATORS OF KIDNEY FAILURE

  • Abnormal protein levels in urine
  • High creatinine levels
  • Abnormal GFR
  • Acute Kidney Injury
  • Low Kidney Function

Diagnoses: Kidney Disease, Chronic Kidney Disease, Fanconi Syndrome, Kidney Failure

EARLY INDICATORS OF BONE LOSS

  • Bone Density Loss
  • Bone Demineralization
  • Bone Weakening
  • Bone Fracture
  • Tooth Loss

Diagnoses: Osteopenia, Osteoporosis, Osteomalacia

WHAT THEY KNEW

Gilead knew that TAF was superior to TDF in both safety and superiority.  Their patent application showed that TAF produced a 10 fold increase in antiviral activity compared to TDF. Gilead knew it had a better option all along and deliberately selected against that option. Profit motivated their decision not to bring TAF to the market since their TDF patent meant big dollars.

WHEN THEY KNEW IT

In 2000, knowing they had a superior, safer alternative to TDF in TAF, they patented TDF.  In 2001, Viread, the first TDF medication went on the market. From 2004-2012, Gilead strung out their patent and released four more TDF drugs, all while knowing TAF was safer and more effective. In July 16, 2012, the FDA approved Truvada® (F/TDF) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in at-risk adults.

WHAT YOU CAN DO

If you or a loved one have been diagnosed with HIV and have taken Viread, Truvada, Atripla, Complera, Stribild or Truvada for PrEP and have subsequently been diagnosed with kidney disease, chronic kidney disease, Fanconi Syndrome, Kidney Failure, Osteopenia, Osteoporosis, or Osteomalacia, contact us today to see if you qualify to make a claim.

Get Your Free Case Review Today

The settlement can run out at anytime. It is important you reach out to us TODAY to see if you or a loved one qualify to recieve funds.

Contact Us

Truvada

Truvada Tied to Kidney Failure and Bone Deterioration

Related Videos

Explore these videos to find out more about the dangers that these products can pose. Explore more injuries HERE. If you'd like to learn More about Periscope Group, feel free to visit HERE. If you'd like to contact us, please call us at 1.800.511.3838.Periscope Group: Making Sure Consumers Don't Become Collateral Damage.

No items found.

Truvada

TRUVADA – WHAT THEY KNEW, WHEN THEY KNEW IT

When HIV/AIDS first hit, panic ensued as it was first considered a death sentence. The pharmaceutical industry was racing to find a treatment or a cure. TDF (later Viread, Truvada, and other names) entered the market and gave hopes of a potential miracle drug, rendering HIV a chronic disease. However, it caused kidney failure and bone deterioration. It seemed that patients were left with a choice – either death by AIDS or kidney failure and bone loss.  Little did they know that Gilead, the manufacturer of Truvada and other such drugs, had a safer, more effective alternative design in their back pocket – TAF. They sat on this alternative in silence for over a decade and moved forward with TDF drugs in order to maximize the profit from its first patent with TDF.

Gilead’s TDF drugs included – Viread, Truvada, Atripla, Complera, and Stribild, Truvada for PrEP

EARLY INDICATORS OF KIDNEY FAILURE

  • Abnormal protein levels in urine
  • High creatinine levels
  • Abnormal GFR
  • Acute Kidney Injury
  • Low Kidney Function

Diagnoses: Kidney Disease, Chronic Kidney Disease, Fanconi Syndrome, Kidney Failure

EARLY INDICATORS OF BONE LOSS

  • Bone Density Loss
  • Bone Demineralization
  • Bone Weakening
  • Bone Fracture
  • Tooth Loss

Diagnoses: Osteopenia, Osteoporosis, Osteomalacia

WHAT THEY KNEW

Gilead knew that TAF was superior to TDF in both safety and superiority.  Their patent application showed that TAF produced a 10 fold increase in antiviral activity compared to TDF. Gilead knew it had a better option all along and deliberately selected against that option. Profit motivated their decision not to bring TAF to the market since their TDF patent meant big dollars.

WHEN THEY KNEW IT

In 2000, knowing they had a superior, safer alternative to TDF in TAF, they patented TDF.  In 2001, Viread, the first TDF medication went on the market. From 2004-2012, Gilead strung out their patent and released four more TDF drugs, all while knowing TAF was safer and more effective. In July 16, 2012, the FDA approved Truvada® (F/TDF) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually-acquired HIV-1 infection in at-risk adults.

WHAT YOU CAN DO

If you or a loved one have been diagnosed with HIV and have taken Viread, Truvada, Atripla, Complera, Stribild or Truvada for PrEP and have subsequently been diagnosed with kidney disease, chronic kidney disease, Fanconi Syndrome, Kidney Failure, Osteopenia, Osteoporosis, or Osteomalacia, contact us today to see if you qualify to make a claim.

Related Videos

Explore these videos to find out more about the dangers that these products can pose. Explore more injuries HERE. If you'd like to learn More about Periscope Group, feel free to visit HERE. If you'd like to contact us, please call us at 1.800.511.3838.Periscope Group: Making Sure Consumers Don't Become Collateral Damage.
No items found.

Related Breaking News

No items found.

Related Breaking News

No items found.

Periscope Group

Making Sure Consumers
Don't Become Collateral
Damage

Additional Resources

Whitewash The Story of a Weed Killer, Cancer, and the Corruption of Science

Whitewash

Known as Monsanto's Roundup by consumers, and as glyphosate by scientists, the world's most popular weed killer is used everywhere from backyard gardens to golf courses to millions of acres of farmland. For decades it's been touted as safe enough to drink, but a growing body of evidence indicates just the opposite, with research tying the chemical to cancers and a host of other health threats.

Read the Book

Get Your Free Case Review Today

Cases are now under review, but there is a limited window to pursue help. If you think you, a friend, or a family member may qualify, get your free case review today before it’s too late.
Fields marked with an asterisk (*) are required.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Info@periscopegroup.com
1.800.511.3838
Periscope Group logo (small)